NR4A1 and breast cancer: In the last two decades, the landscape of systemic treatment for advanced BC has changed significantly, with main developments occurring in the treatment of hormone receptor-positive (HR+)/HER2-negative (HER2-) as well as HER2-positive (HER2+) cases [4].